Cresomycin is an experimental antibiotic. It binds to the bacterial ribosome in both Gram-negative and Gram-positive bacteria, and it has been found to be effective against multi-drug-resistant stains of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. It belongs to the bridged macrobicyclic oxepanoprolinamide antibiotics, which have similarities with lincosamides antibiotics.
Cresomycin is an experimental antibiotic. It binds to the bacterial ribosome in both Gram-negative and Gram-positive bacteria, and it has been found to be effective against multi-drug-resistant stains of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. It belongs to the bridged macrobicyclic oxepanoprolinamide antibiotics, which have similarities with lincosamides antibiotics.
Cresomycin has been specially designed to bind in a preorganised way with the bacterial ribosome, resulting to improved binding. This allows cresomycin to overcome the ribosomal methylase genes that are responsible for the bacterial resistance against other antibiotics that bind to the peptidyl transferase center of the ribosome, such as lincosamides. Cresomycin was synthesized based on iboxamycin, another oxepanoprolinamide antibiotic, with the addition of a 10-membered ring to it.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).